Host-targeted niclosamide inhibits C. difficile virulence and prevents disease in mice without disrupting the gut microbiota | Nature Communications
Therapeutic Antibodies to Track in 2017, Part I
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection | NEJM
Figure 1 | Bezlotoxumab for Preventing Recurrent Clostridioides difficile Infection: A Narrative Review from Pathophysiology to Clinical Studies | SpringerLink
What is the potential of antivirulence antimicrobial therapy? – Walking to the light
Structural basis of strain-specific differences in bezlotoxumab potency... | Download Scientific Diagram
Zinplava (bezlotoxumab) for the Treatment of Clostridium Difficile Infection - Clinical Trials Arena
Bezlotoxumab: A Novel Agent for the Prevention of Recurrent Clostridium difficile Infection - Kufel - 2017 - Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - Wiley Online Library
Zinplava (bezlotoxumab) for the Treatment of Clostridium Difficile Infection - Clinical Trials Arena
Small Molecules Take A Big Step Against Clostridium difficile: Trends in Microbiology
Actoxumab/Bezlotoxumab
JCI Insight - Human C. difficile toxin–specific memory B cell repertoires encode poorly neutralizing antibodies
Mechanism of Action for ZINPLAVA™ (bezlotoxumab)
Mapping the binding sites for CSPG4, FZDs, and bezlotoxumab in TcdB... | Download Scientific Diagram
Comparing the efficacy and safety of faecal microbiota transplantation with bezlotoxumab in reducing the risk of recurrent Clostridium difficile infections: a systematic review and Bayesian network meta-analysis of randomised controlled trials
Zinplava - FDA prescribing information, side effects and uses
Bezlotoxumab: an emerging monoclonal antibody therapy for prevention o | BTT
Bezlotoxumab Overview - Creative Biolabs
Bezlotoxumab Stories - Wattpad
Mechanism of Action and Epitopes of Clostridium difficile Toxin B-neutralizing Antibody Bezlotoxumab Revealed by X-ray Crystallography - Journal of Biological Chemistry
Bezlotoxumab for the prevention of Clostridium difficile inf | IDR
Mechanism of Action and Epitopes of Clostridium difficile Toxin B-neutralizing Antibody Bezlotoxumab Revealed by X-ray Crystallography - ScienceDirect
Frontiers | Development of Neutralizing and Non-neutralizing Antibodies Targeting Known and Novel Epitopes of TcdB of Clostridioides difficile | Microbiology
Nonantimicrobial drug targets for Clostridium difficile infections | Future Microbiology
Immune response against Clostridioides difficile and translation to therapy - Kanika Sehgal, Sahil Khanna, 2021
Mechanism of Action and Epitopes of Clostridium difficile Toxin B-neutralizing Antibody Bezlotoxumab Revealed by X-ray Crystallography - Journal of Biological Chemistry
